Non-invasive metabolic tracking for employer wellness.
ViBo Health is developing DigiScan™, a non-invasive Metabolic Intelligence Platform designed to make employer wellness programs more measurable, engaging, and actionable through rapid, repeatable metabolic measurements from the finger.
ViBo Health is a medical technology company developing DigiScan™, a Metabolic Intelligence Platform for employer wellness. DigiScan uses magnetic resonance spectroscopy (MRS), proprietary sensing hardware, signal processing, and artificial intelligence to measure metabolic signals non-invasively from the finger and convert those measurements into longitudinal metabolic information.
ViBo Health’s initial commercial focus is self-insured employers and workplace wellness programs. DigiScan is designed to reduce the friction associated with traditional health measurements by making metabolic tracking rapid, non-invasive, and repeatable enough to provide frequent objective feedback over time.
ViBo Health has generated its first in vivo human finger data and is advancing DigiScan toward employer pilot deployments.
ViBo Health’s mission is to provide more frequent insight into metabolic health through simple, non-invasive measurement and actionable feedback.
The company’s long-term vision is a platform that helps people see meaningful changes in their own metabolic patterns over time and make more informed wellness decisions.
Employers invest in wellness programs, preventive health, and lifestyle interventions, but participation and sustained engagement remain difficult. Many programs rely on infrequent measurements, self-reported behavior, or feedback that arrives too slowly to reinforce change.
ViBo Health is developing DigiScan to add frequent, objective metabolic feedback to employer wellness programs, helping participants see how their metabolic health changes over time.
DigiScan™ is a non-invasive metabolic tracking platform under development by ViBo Health. DigiScan uses magnetic resonance spectroscopy, proprietary sensing technologies, advanced signal processing, and artificial intelligence to measure metabolic signals from the finger.
DigiScan is designed for rapid, repeatable measurement outside the traditional laboratory environment, supporting longitudinal metabolic tracking rather than isolated point-in-time measurements.
DigiScan integrates proprietary technologies for non-invasive metabolic measurement and longitudinal analysis, including:
Generated using an advanced DigiScan prototype in 2026.
Six Letters of Intent, including two multinational organizations.
ViBo Health has conducted collaborative work with UCLA and Los Alamos National Laboratory. Technology development has also received support from NIST and the State of New Mexico.
ViBo Health continues to expand its intellectual property portfolio.
Founder & CEO
ViBo Health’s team combines experience in medical devices, magnetic resonance technologies, artificial intelligence, engineering, commercialization, and regulatory strategy.
DigiScan’s initial employer-wellness use is focused on general metabolic tracking and does not involve medical claims.
For future clinical applications, ViBo Health anticipates pursuing U.S. FDA Class II 510(k) clearance, with the specific pathway depending on intended use and supporting evidence.
ViBo Health is a medical technology company developing DigiScan™, a non-invasive Metabolic Intelligence Platform for employer wellness programs. DigiScan combines magnetic resonance spectroscopy, proprietary sensing and signal processing, and AI-assisted analytics to provide rapid, repeatable metabolic measurements from the finger. ViBo Health is developing DigiScan to make longitudinal metabolic tracking more accessible and to provide objective feedback that can support participation and engagement in employer wellness programs.
DigiScan™ is under development. It has not been cleared or approved by the U.S. Food and Drug Administration (FDA) and is not intended to diagnose, treat, cure, mitigate, or prevent disease.
Future clinical applications would require FDA clearance before commercial use.
For company background, investor inquiries, partnership discussions, or media requests, contact ViBo Health.